Myriad Genetics (MYGN)

The company’s test menu spans several areas of healthcare. In oncology, products such as BRACAnalysis CDx, MyRisk, MyChoice CDx, Precise Tumor, and Prolaris help evaluate hereditary cancer risk, identify relevant biomarkers, or inform treatment choices for certain cancers. In women’s health and reproductive medicine, tests such as Foresight, Prequel, and SneakPeek address carrier screening, prenatal screening, and early pregnancy-related insights. GeneSight is used in mental health care to provide pharmacogenomic information that may help clinicians consider how a patient could respond to certain medications.

Myriad’s business is based largely on processing clinical samples, generating genetic data, interpreting results, and delivering reports that can be used by healthcare providers. The company operates mainly in the United States, which accounts for most of its revenue, while also serving select international markets.

Demand for Myriad’s services is linked to the adoption of genetic testing, insurance reimbursement, physician awareness, clinical guideline support, and advances in precision medicine. The company operates in a competitive diagnostics market where scientific validation, payer coverage, turnaround time, and ease of use are important. For investors, MYGN offers exposure to the expanding role of genetics in cancer care, reproductive health, mental health, and personalized medicine.